U.S. markets closed

Takeda Pharmaceutical Company Limited (4502.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
Add to watchlist
3,689.00+28.00 (+0.76%)
As of 10:50AM JST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3,661.00
Bid3,689.00 x 0
Ask3,690.00 x 0
Day's Range3,671.00 - 3,699.00
52 Week Range2,993.00 - 3,842.00
Avg. Volume5,627,255
Market Cap5.728T
Beta (5Y Monthly)1.00
PE Ratio (TTM)13.26
EPS (TTM)278.11
Earnings DateJul 28, 2022 - Aug 01, 2022
Forward Dividend & Yield180.00 (4.90%)
Ex-Dividend DateSep 29, 2022
1y Target Est4,257.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for 4502.T

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      Japan's Takeda forecasts rebound despite full-year profit drop

      Japan's Takeda Pharmaceutical Co said on Wednesday its 12-month operating profit slid 9.5%, although the country's largest drugmaker forecast a rebound for the current year. Chief Executive Christophe Weber said that core operating profit, which strips out impairments and other non-recurring items, would likely exceed 1 trillion yen this fiscal year, and the company's financials would become clearer now that its 2019 absorption of Shire Plc is complete. Takeda is domestically producing the COVID-19 vaccine, developed by Novavax Inc, which was approved by Japanese regulators last month.

    • Business Wire

      Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022

      OSAKA, Japan, May 11, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product launches and strength across its key business areas.

    • GlobeNewswire

      CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

      Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases CENTOGENE and Takeda extend contract to continue providing access to genetic testing for patients with rare metabolic and rare neurodegenerative diseasesThe global market access and expansion partnership initially established in 2015 aims to provide an efficient and timely diagnosis to patientsDiagnosis remains crucial for patients, leading them towards suitable readily available t